Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP

By Khorri Atkinson · June 10, 2022, 9:10 PM EDT

Two Federal Circuit judges did not seem fully convinced Friday that three Stanford University patents licensed to CareDx Inc., developer of commercial tests for kidney transplant rejections, are valid under the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

CareDx, Inc. v. Natera, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

October 08, 2021

Recent Articles By Khorri

July 28, 2022
Judge Mulls Feds', Tobacco Cos.' Decree On Health Warnings
July 01, 2022
Ky. Trial Judge Vacancy Tees Up Likely Biden-McConnell Deal
May 25, 2022
11th Circ. Nixes Suit By Atty Who Ended Mental Health Checks
May 23, 2022
Judge Skeptically Probes Fate Of FDA's Cigar Regulation
May 16, 2022
Providers Say 9th Circ. Ruling Helps BCBS Antitrust Case
April 11, 2022
DOJ Attys Escape Subpoena To Testify In Wage-Fixing Trial
March 24, 2022
Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal
March 22, 2022
3rd Circ. Upholds FTC Bid To Pause NJ Hospital Merger
March 18, 2022
DC Judge Ends 'Dormant' LabMD Suit Against FTC Attys
January 19, 2022
Biden Seeks To Expel Migrant Families; DC Circ. Is Skeptical